10 Access blog
Barriers to access to health services in Colombia
Access barriers are caused by multiple factors, some authors affirm that among these causes, which also promote inequity, are the privatized model of pharmaceutical innovation and the condition of monopoly ...

Barriers to access to health services in Colombia

Ornella Moreno Mattar

Ornella Moreno Mattar

Health Administrator,
MSc in Public Policy,
health economics lead

Share on networks:

Share on linkedin
Share on facebook
Share on twitter

Since the World Health Assembly in 1975, there was evidence of the need for countries to have advice on the “selection and acquisition, at affordable prices, of approved quality drugs” (1), although this need referred to drugs essential to treat diseases of interest in public health, at present and taking into account that the right to health must be guaranteed to the entire population, this need is more latent and widespread than ever.

 

However, what does guaranteeing the right to health consist of? in the articulation of different factors such as universal health coverage and timely and quality effective access to health facilities, services and technologies.

 

The World Health Organization has proposed that, specifically to contribute to access to medicines, countries should formulate pharmaceutical policies that include five dimensions (see figure 1):

  • Availability: sufficient number of health establishments, goods and services. This depends on investment in infrastructure, research, development, and the manufacturing, provision, distribution, and marketing of drugs and services.
  • Affordability: refers to the relationship between the price of the product and the ability of the payer to assume its cost (whether for public spending, private spending or out-of-pocket expense).
  • Accessibility: health facilities, goods and services accessible to all. This dimension is related to the dispensing and efficiency processes of the pharmaceutical service.
  • Acceptability: use of drugs in the prescription, administration and promotion of adherence to treatments.
  • Quality: transversal to all dimensions and guarantor of the efficacy and safety of drugs (1).

 

Following these WHO recommendations and in line with the evident needs in the country to guarantee timely access to quality medicines, in Colombia, during 2012 and through CONPES 155 “National Pharmaceutical Policy”, the National Government stated that “ The central problem of the national pharmaceutical situation was unequal access to medicines and poor quality of care ”and established a series of strategies and actions to address this situation, however, almost a decade later this problem is still evident (2 ).

 

Analyzes carried out have shown that, once the drug price control measures were implemented (one of the strategies proposed in the pharmaceutical policy), drug prices decreased by 43%, but pharmaceutical spending on health almost fell. It doubled, which contrasts with the access problems that Colombians present, both in the contributory and subsidized regimes, which is reflected in the number of guardianships in health in Colombia, which represent the largest participation in the total of guardianships based in the country since 2008 (2). For example, in 2018 every 2.5 minutes a guardianship was filed for violation of the right to health in Colombia (3).

What are the causes of access barriers in Colombia?

 

Access barriers are caused by multiple factors, some authors affirm that among these causes, which also promote inequity, are the privatized model of pharmaceutical innovation and the monopoly condition that has been established with the granting of intellectual property rights, that have allowed the establishment of high prices in medicines (1).  

 

Particularly in Colombia, the causes oscillate between the structural, the intersectoral and the specific of the health system. Among the first causes (structural and intersectoral) we have health inequalities, evidenced in populations with great financial limitations, low health education and high vulnerability, conditions that exacerbate some of the access barriers, especially economic barriers such as transportation and travel or copayments for medications and exams (4).

 

Reviewing the Index of Access to Health Services in Colombia, the more specific causes of access barriers can be observed, which can be addressed more immediately by the health system, for example, the lack of beds and professionals health of various specialties, the number of medical and nursing professionals per 10,000 inhabitants, insufficient installed capacity and infrastructure and, in many regions, low use of available services (3).

 

A clear example is access to sexual and reproductive health services, where out-of-pocket spending is an important barrier, including care for low-income pregnant women and remote areas (3).

 

Another cause of barriers to effective access to medicines is shortages, in this sense, according to the INVIMA Medicine Shortage Management Report until 2018, the insufficient number of suppliers, the discontinuation of products and manufacturing problems ( quality) have been the main causes of shortages in the country (5).

 

What can be done to lower these barriers?

 

There are many challenges to guarantee access to medicines, and responsibility is distributed among the different actors of the Health System, some actions implemented, not only in Colombia but in several countries, to favor access to medicines are:

 

  • Establish multilateral agreements between countries that include not only regional purchases, but also technology transfers such as raw materials.
  • Relax the conditions of the agreement on "Aspects of intellectual property rights related to trade".
  • Implement Medicines Patent Pools, that is, negotiating voluntary licenses with patent holders through participation in common funds.
  • Carry out centralized price negotiations, such as the model that has been implemented in Colombia for Hepatitis.
  • Regulate drug prices through different mechanisms, such as international referencing, without discouraging innovation and generating technological lag.
  • Apply exemptions from customs taxes for medicines used in the treatment of diseases of interest in public health or orphans.
  • Ensure transparency in the implementation and compliance of the pharmaceutical market regulation policies.
  • Implement measures that improve the logistics of drug distribution: infrastructure and transportation.
  • Guarantee primary care centered on the patient that allows guaranteeing adherence to treatments.
  • Use telemedicine to access a larger population and rural areas through strategies that combine extramural programs and remote connection (1).
  • Strengthen the hospital infrastructure by identifying the needs of the different regions of the country.
  • Improve the conditions and opportunities for training human talent in health.

 

The successful implementation of most of these actions requires greater communication and articulation between the Government, civil society, academia and the private sector, which allows to promote the efficiency of the health system and reduce the difficulties that patients currently suffer in the country and which are reflected in a large number of guardianships, evidence of the violation of their right to health.

Bibliography

  1. Ledezma-Morales M, Amariles P, Augusto F, Buenaventura R. Strategies to promote access to drugs of interest in public health: structured review of the literature. Rev Fac Nac Public Health. 2019; 38 (1): 1–14.
  2. Figueredo De Pérez DA, Vargas-Chaves I. Access to medicines in Colombia and the contours of a right and a pharmaceutical policy halfway through. Justice. 2020; 25 (37): 125–50.
  3. National Health Observatory. Summary Access to Health Services in Colombia. Bogotá DC; 2019.
  4. Hilarión-Gaitán L, Díaz-Jiménez D, Cotes-Cantillo K, Castañeda-Orjuela C. Inequalities in health by regime of affiliation to the health system in events of mandatory notification, Colombia, 2015 TT - Inequalities in health according to affiliation regime and events notified to the Surveillance System (Sivigila) in Colombia, 2015. Biomedica [Internet]. 2019 Dec 1; 39 (4): 737–47. Available from: https://pubmed.ncbi.nlm.nih.gov/31860184
  5. INVIMA (Food and Drug Surveillance Institute). Management report on the shortage of medicines in Colombia 2013-2018. 2018; 1–4. Available from: https://www.invima.gov.co/desabastecimiento-

 

Share on networks:

Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on twitter
Twitter
Other publications
Market Access y pacientes
Market access

Market Access: A Patient-Centered Vision

As we have seen in previous posts, market access in the pharmaceutical sector allows therapies to reach the largest number of patients who need them, breaking down barriers of availability and affordability.

Read more

Subscribe now